76 related articles for article (PubMed ID: 20031962)
1. Advances in target therapy for lung cancer.
Mitsudomi T
Jpn J Clin Oncol; 2010 Feb; 40(2):101-6. PubMed ID: 20031962
[TBL] [Abstract][Full Text] [Related]
2. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
3. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
7. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
Agelaki S; Georgoulias V
Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
[TBL] [Abstract][Full Text] [Related]
9. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
10. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
12. [Driver gene mutation and targeted therapy of lung cancer].
Mitsudomi T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):285-90. PubMed ID: 23507588
[TBL] [Abstract][Full Text] [Related]
13. Drug development: portals of discovery.
Bates SE; Amiri-Kordestani L; Giaccone G
Clin Cancer Res; 2012 Jan; 18(1):23-32. PubMed ID: 22215903
[TBL] [Abstract][Full Text] [Related]
14. Metastatic gastric cancer - focus on targeted therapies.
Meza-Junco J; Sawyer MB
Biologics; 2012; 6():137-46. PubMed ID: 22807624
[TBL] [Abstract][Full Text] [Related]
15. [Challenge and up-to-date of molecule target therapy in lung cancer].
Han BH
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):83-5. PubMed ID: 17445464
[No Abstract] [Full Text] [Related]
16. [Synchronous primary lung adenocarcinomas with epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene: report of a case].
Wang Y; Yang L; Jiang HJ; Chen JY; Zhang HL; Da JP
Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):298-299. PubMed ID: 29690673
[No Abstract] [Full Text] [Related]
17. Advances in lung cancer.
Pacheco JM; Dimou A; Bunn PA
Oncotarget; 2017 Oct; 8(45):78247-78248. PubMed ID: 29108218
[No Abstract] [Full Text] [Related]
18. Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment.
Pandey M; Chandramohan K
World J Surg Oncol; 2003 Jul; 1(1):9. PubMed ID: 12848894
[No Abstract] [Full Text] [Related]
19. [Current condition and advances in the target treatment of lung cancer].
Zhou Q
Zhongguo Fei Ai Za Zhi; 2003 Dec; 6(6):434-40. PubMed ID: 21310125
[No Abstract] [Full Text] [Related]
20. [More attention should be devoted to molecular target therapy of lung cancer in our country].
Zhou Q; Sun Y
Zhongguo Fei Ai Za Zhi; 2004 Aug; 7(4):267-9. PubMed ID: 21241540
[No Abstract] [Full Text] [Related]
[Next] [New Search]
